Autosomal Dominant Polycystic Kidney Disease (ADPKD) Terminated Phase 2 Trials for Tesevatinib (DB11973)

Also known as: Autosomal Dominant Polycystic Kidney Disease / Polycystic Kidney Disease, Autosomal Dominant / ADPKD (Autosomal Dominant Polycystic Kidney Disease) / ADPKD / Polycystic Kidney, Autosomal Dominant / Autosomal Dominant Polycystic Kidney Disease (ADPKD / Autosomal Dominant Polycystic Kidney / Kidney, Polycystic, Autosomal Dominant / Autosomal Dominant Polycystic Kidney Disease (ADPKD) / Congenital cystic kidney disease NOS / Congenital cystic kidney disease

IndicationStatusPhase
DBCOND0050861 (Autosomal Dominant Polycystic Kidney Disease (ADPKD))Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02616055Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101Treatment